Triumeq

(Abacavir, dolutegravir, and lamivudine)

Triumeq

Drug updated on 11/30/2023

Dosage FormTablet (oral; 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine) PD Tablet (oral; 60 mg of abacavir, 5 mg of dolutegravir, and 30 mg of lamivudine)
Drug ClassIntegrase strand transfer inhibitor [INSTI]) (dolutegravir), Nucleoside analogue reverse transcriptase inhibitors (abacavir, and lamivudine)
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg.

Product Monograph / Prescribing Information

Document TitleYearSource
Triumeq (abacavir, dolutegravir, and lamivudine) prescribing Information.2023ViiV Healthcare Durham, NC

Randomized Controlled Trials

Clinical Practice Guidelines